Trial Profile
A multicenter, randomized, 52-week, double-blind, parallel-group, active-controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary) ; Indacaterol/mometasone; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms IRIDIUM
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 29 Jun 2023 Results of a post-hoc analysis whether baseline eosinophil levels affect efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) in patients with inadequately controlled asthma published in the Respiratory Medicine
- 09 Mar 2023 Results of post hoc analysis , assessing the efficacy of MF/IND/GLY in asthma patients with and without PAL, published in the Respiratory Medicine
- 25 Jul 2022 Results of post-hoc analysis assessing efficacy and safety of IND/MF versus SAL/FLU in Asian patients with inadequately controlled asthma from two (PALLADIUM and IRIDIUM) published in the Journal of Asthma